# A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects

> **NCT03586076** · PHASE1 · COMPLETED · sponsor: **JHL Biotech, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **BIOLOGICAL:** JHL1922
- **BIOLOGICAL:** dornase alfa

## Key facts

- **NCT ID:** NCT03586076
- **Lead sponsor:** JHL Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2018-06-22
- **Final completion:** 2019-05-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586076, "A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03586076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*